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Stroke is the third major cause of death and long-term
disability in most developed countries, with very lim-
ited chance for effective treatments. The mechanisms
that trigger ischemic brain damage include a plethora
of biochemical and cellular events, such as glutamate-
mediated excitotoxicity, generation of reactive oxygen
species, DNA damage and inﬂammation. In focal
ischemia, primary neuronal death appears rapidly in
the core area and is followed by secondary death in
the ischemic penumbra that evolves from the delayed
activation of multiple death pathways. Thus, the
infarct takes several days to mature and recruits a
myriad of processes that, depending on the threshold
of single neuron vulnerability, determine the ﬁnal dam-
age entity. Identifying the factors setting the limit of
neuronal resistance will disclose new targets for mini-
mizing development of the lesion. A large repertoire of
genes is activated by transcription factors induced in
brain ischemia, including hypoxia inducible factor-1,
p53, interferon regulatory factor-1 activating transcrip-
tion factor-2, signal transducer and activator of tran-
scription 3 and nuclear factor-kappaB (NF-jB) [1].
NF-jB is a key regulator of both inﬂammation and
cell death and has been proposed as suitable target for
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Nuclear factor-kappaB (NF-jB) has been proposed to serve a dual func-
tion as a regulator of neuron survival in pathological conditions associated
with neurodegeneration. NF-jB is a transcription family of factors com-
prising ﬁve different proteins, namely p50, RelA ⁄p65, c-Rel, RelB and p52,
which can combine differently to form active dimers in response to external
stimuli. Recent research shows that diverse NF-jB dimers lead to cell death
or cell survival in neurons exposed to ischemic injury. While the p50 ⁄p65
dimer participates in the pathogenesis of post-ischemic injury by inducing
pro-apoptotic gene expression, c-Rel-containing dimers increase neuron
resistance to ischemia by inducing anti-apoptotic gene transcription. We
present, in this report, the latest ﬁndings and consider the therapeutic
potential of targeting different NF-jB dimers to limit ischemia-associated
neurodegeneration.
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the treatment of brain ischemia [1–3]. In this report we
review the most recent advances in understanding the
mechanisms responsible for the dual effect produced
by NF-jB in the post-ischemic injury and for predict-
ing possible new experimental approaches.
Molecular activation of NF-jB
In the past two decades, much work focused on
NF-jB family proteins has proposed this ubiquitously
expressed transcription factor as a pleiotropic regulator
of target genes controlling physiological function in
the nervous system. In mammals, the NF-jB family
comprises ﬁve members, sharing an N-terminal 300
amino acid Rel-homology domain (RHD), which is
identical in 35–61% of all NF-jB family proteins: p65
(RelA), RelB, c-Rel, p50 ⁄p105 (NF-jB1), and
p52 ⁄p100, which are encoded by RELA, RELB, REL,
NFKB1 and NFKB2 respectively. The RHD domain
allows dimerization, nuclear translocation and DNA
binding. Among the members of the NF-jB family,
only p65, c-Rel and RelB are directly able to activate
the transcription of target genes. The transcriptional
capacities of p50 and p52, which are initially synthe-
sized as large precursors called p105 and p100, are
dependent on dimerization with p65, c-Rel or RelB
[4,5]. In the absence of stimuli, the members of the
NF-jB family form homodimers and heterodimers that
are present in an inactive state in the cytoplasm bound
to the jB inhibitory proteins (IjBs) (IjBa, IjBb, IjBe,
IjBc and Bcl-3, IjBf, the precursor proteins p100 and
p105), which share multiple ankyrin repeat domains
necessary for interacting with the RHD. In the estab-
lished model, these proteins retain NF-jB dimers in
the cytoplasm by masking the NF-jB nuclear localiza-
tion sequence and the DNA-binding domain. Indeed,
IjBa leads a constant shuttling of the p50 ⁄p65 com-
plex between the nucleus and the cytoplasm [6]. In
stimulated cells, IjBa is phosphorylated and degraded,
thus favouring the nuclear localization of the NF-jB
complex where it binds to jB sites with the consensus
sequence GGGRNNYYCC (N = any base, R = pur-
ine, Y = pyrimidine) and activates the transcription of
a number of target genes. Among the numerous genes
regulated by NF-jB is IjBa. Newly synthesized IjBa
can enter the nucleus, remove NF-jB from DNA and
export the complex back to the cytoplasm, therefore
providing a feedback mechanism to restore the original
latent state. Two different intracellular pathways acti-
vate NF-jB, namely the ‘classic’ pathway and the
‘alternative’ pathway, which result in the release of
NF-jB from its inhibitors and in the nuclear localiza-
tion of NF-jB [7]. The canonical pathway of NF-jB
activation passes through the activation of an IjB
kinase (IKK) complex, composed of two catalytic
subunits (IKK1 ⁄a and IKK2 ⁄b) and a regulatory sub-
unit NF-jB essential modulator (NEMO) ⁄ IKKc.
Upon stimulation, IKK2 is involved in the phosphory-
lation of two N-terminal serines within the IjBs, lead-
ing to their ubiquitination and degradation through
the proteasome pathway. The alternative pathway
involves the processing and cleavage of the p100
precursor to p52, which is triggered by the phosphory-
lation of p100 by NF-jB-inducing kinase and of
IKK1. In the alternative pathway, p52 mostly dimeriz-
es with RelB in response to a limited number of
stimuli such as lympotoxin B, CD40 ligand and B-cell
activating factor operating in the immune system [8].
On the contrary, the canonical IKK2-dependent path-
way is induced by a wide variety of stimuli. Among
these are neurotransmitters such as glutamate [9],
dopamine [10–12] and norepinephrine [13], as well as
growth factors [14–17], beta amyloid peptide [18],
oxidative stress, UV light and cytokines such as tumor
necrosis factor-alfa and interleukin (IL)-1 [19] or
tumour necrosis factor-like weak inducer of apoptosis
(TWEAK) [20].
In brain neurons, diverse glutamate receptor sub-
types, namely the ionotropic N-methyl-d-aspartate
(NMDA) and kainate receptors and the metabotropic
glutamate (mGlu) receptors, lead to NF-jB activation.
Ca2+ signalling plays a fundamental role in NF-jB
activation by ionotropic glutamate receptors [9,21]. In
hippocampal neurons the opening of calcium channels
is indispensable for basal NF-jB activity. Three cell-
ular sensors of Ca2+ levels – calmodulin, protein
kinase C (PKC) and the p21(ras) ⁄phosphatidylinositol
3-kinase (PI3K) ⁄Akt pathway – are simultaneously
involved in NF-jB activity [22]. Stimulation of both
the calmodulin kinase II and Akt kinase pathways are
responsible for the upregulation of the p65 subunit of
NF-jB [22]. Activation of PI3K, mitogen-activated
protein kinase kinase (MEK) and PKC by mGlu5
agonists [23] or leptin [24] lead to activation of the
c-Rel subunit in neuronal cells.
NF-jB in the central nervous system
In the central nervous system, NF-jB factors act as
regulators of growth, differentiation and adaptive
responses to extracellular signals [25–27]. The activity
of NF-jB is developmentally regulated [28,29]. It has a
role in adult neurogenesis [30] and in the growth of
neuronal processes of maturing neurons [31–35]. Inhib-
iting the constitutive DNA-binding activity of NF-jB
blocks differentiation and induces apoptosis. This was
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reported in diverse primary neurons [29,32–34,36] and
was related to the downregulation of NF-jB-mediated
transcription of the B-cell lymphoma 2 (Bcl-2) family
of anti-apoptotic genes [29,36]. The apoptosis of cells
deprived of NF-jB activity indicates that there is a
threshold of constitutive NF-jB activation below
which the expression of anti-apoptotic genes and neu-
ron survival are impaired. The presence of NF-jB in
the synaptic regions has also suggested that NF-jB
might be regarded as a signal transducer that transmits
transient synaptic signals to the nucleus and has a role
in behaviour, learning and memory formation [25,37].
By using a jB decoy DNA, the involvement of NF-jB
has been shown in long-term retention of fear memory
[38,39], in inhibitory avoidance memory [40] and in
spatial long-term memory [41]. A forebrain neuronal
conditional NF-jB-deﬁcient mouse model conﬁrmed
the prominent role of neuronal NF-jB in memory and
cognition by demonstrating that loss of neuronal
NF-jB speciﬁcally impairs spatial long-term memory
formation in the Morris water maze task, whereas the
nonspatial working ⁄ episodic memory is unaltered [42].
p50, p65 or c-Rel factors were found to be involved in
mechanisms of cognition [26,43–46]. p50) ⁄ ) mice pres-
ent impaired learning in an active avoidance assay [43]
and show defects of short-term memory in the place
recognition test [30]. They also show reduced anxiety-
like behaviour in exploratory drive and anxiety tests
[47]. The p65-deﬁcient mice rescued from embryonic
death on a TNFR1) ⁄ ) background display spatial
learning defects when challenged in a radial arm maze
[44]. The c-Rel) ⁄ ) mice display hypomotility and
impaired hippocampal-dependent functions in contex-
tual long-term memory and passive avoidance tasks
[23,45]. The long-term memory deﬁcit in c-Rel) ⁄ ) mice
correlates with defects in the long-term depression
(LTD) of Schaffer-collateral synapses in the hippocam-
pus, which is dependent on activation of the mGlu5
receptor [23]. These ﬁndings suggest that c-Rel is
needed for basal synaptic transmission and mainte-
nance of LTD in the hippocampus, whereas other
members of the NF-jB family might be responsible for
the induction of LTD and the late phase of long-term
potentiation [42].
NF-jB complexes – bifunctional
regulators of neuronal vulnerability
Besides regulating neurodevelopment and synaptic
activity, NF-jB factors appear to be centrally involved
in various pathological conditions associated with
neurodegeneration [48–50]. These include trauma and
ischemia [50–54], Alzheimer’s and Parkinson’s diseases
[55–57] or Huntington’s disease [58]. The bifunctional,
neurodegenerative and neuroprotective role of NF-jB
has been widely debated in the last years [59–61]. Acti-
vation of NF-jB by tumor necrosis factor protects hip-
pocampal cells from oxidative stress [62,63], promotes
neuron survival to excitotoxic noxae [64,65] and res-
cues cells from b-amyloid-induced apoptosis [66]. Fur-
thermore, activation of NF-jB has a role in brain
tolerance, the adaptive response induced by a sub-
threshold stress that preserves brain health against
acute injury [67]. Among the NF-jB target genes
involved in neuroprotection is the inhibitory protein,
IjBa, which, by hampering aberrant NF-jB activation
caused by severe ischemia or epilepsy [67], prevents
brain damage. By contrast, diverse studies support the
causative role of NF-jB in the degeneration of brain
neuronal cells exposed to toxic stimuli. NF-jB pro-
motes cell death in neurons exposed to excitotoxins
in vivo [49,68] or in vitro [69–71], DNA damage [72],
dopamine [10], mutant huntingtin [58] and b-amyloid
peptide [57,73–75]. Either neurotoxic [71,76] or ami-
loidogenic [75] processes associated with NF-jB activa-
tion are prevented by IjBa or IKK2 inhibitors [77].
With the aim to clarify which determinants make
the inducible form of NF-jB a cell death factor or a
cell-survival factor in pathological conditions, recent
research has shown that different NF-jB complexes
are involved in the opposite regulation of neuron via-
bility. While aberrantly activated p50 ⁄p65 dimers con-
tribute to the apoptotic program, the c-Rel-containing
dimers increase the resistance of injured neuronal cells
to further damage. Studies of glutamate and IL-1b in
primary neurons and hippocampal slices showed that
NMDA receptor activation is associated with the rapid
induction of p50 and p65 subunits from NF-jB to
form the p50 ⁄p65 dimer (Fig. 1) [70,71,76]. The neuro-
protection elicited by IL-1b, a cytokine involved in
mechanisms of brain tolerance [78], is associated with
the activation of c-Rel in addition to p50 and p65
factors (Fig. 2). Targeting p65 expression with anti-
sense oligodeoxynucleotides prevents glutamate-
mediated cell death. Targeting c-Rel, or using brain
hippocampal slices from c-Rel) ⁄ ) mice, abolishes the
IL-1b neuroprotection without affecting glutamate
toxicity [70]. In line with this evidence, the activation
of NF-jB p50 ⁄p65 was found to mediate the neuro-
toxic effect produced by oxidative stress in HT22
immortalized hippocampal cells [79] and to contribute
to both neurotoxic and amyloidogenic effects produced
by the ﬁbrillar form of b-amyloid peptide in cultured
neuronal models [75]. The p50 ⁄p65 dimer is activated
in the ﬁrst hour of exposure to b-amyloid and precedes
the expression of a characteristic pro-apoptotic gene
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panel [75]. The relevance of c-Rel activation in neuro-
nal cells was ﬁrst outlined by evidence that the over-
expression of c-Rel reproduces the anti-apoptotic
response of nerve growth factor in sympathetic neurons
and of insulin-like growth factor-1 in cerebellar and
hippocampal cells [32,80]. Further studies showed that
the neuroprotective effects produced by S100 calcium-
binding protein B against NMDA toxicity in hippo-
campal neurons [81], or by agonists at mGlu5 receptors
against b-amyloid- [82] and 1-methyl-4-phenylpyridini-
um toxicity [83], rely on the speciﬁc activation of
c-Rel ⁄p65 and c-Rel ⁄p50 dimers. Targeting c-Rel factor
using the RNA interference technique or c-Rel) ⁄ ) neu-
rons abolishes the expression of the anti-apoptotic
genes manganese superoxide dismutase (MnSOD) and
Bcl-X(L) and neuroprotection against b-amyloid toxic-
ity by mGlu5 receptor agonists (Fig. 2) [82].
NF-jB complexes in brain ischemia
After an ischemic insult to the brain, NF-jB is rapidly
activated in neurons and glial cells and, being a regula-
tor of inﬂammation and apoptosis, it has been
proposed to contribute to the subacute pathogenesis of
the post-ischemic injury [50,51,53,84,85]. NF-jB acti-
vation and neurodegeneration results from oxidative
stress and excitotoxicity and, at least in part, from the
expression of TWEAK and its Fn14 receptor [20].
Using mice that express a super-repressor form of
IjBa under the transcriptional control of neuron-
speciﬁc enolase or glial ﬁbrillary acidic protein, it was
demonstrated that only the NF-jB loss in neurons,
and not that in astrocytes, reduces the infarct size [86].
Likewise, loss of IKK2 by neuron-targeted deletion or
expression of a transdominant negative mutant of
IKK2 in forebrain neurons reduces ischemic brain
damage in a similar way to that observed in neuron
plus glia-deﬁcient IKK2 knockout mice. Activation of
IKK2 by a constitutively active transdominant mutant
of IKK2 in neurons increases the infarct size [85]. It is
noteworthy that neuroprotection is evident when
NF-jB inhibitors lower, but do not totally abolish,
NF-jB activity [85–87]. When inhibition lowers
the NF-jB activity below the constitutive threshold
level, the neuronal damage is exacerbated [65], in line
with evidence that a critical NF-jB activity is required
for cell survival and either aberrant activation or total
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Fig. 1. NF-jB signaling in ischemia, In brain ischemia, NF-jB
becomes rapidly activated in response to diverse extracellular sig-
nals (including glutamate and TWEAK) and to intracellular events
[such as the generation of reactive oxygen species (ROS) and the
elevation of Ca2+ content]. Most NF-jB activation involves the
p50 ⁄ p65 dimer, which induces transcription of the pro-apoptotic
Bim and Noxa genes, promoting neuronal cell death. AMPA, alpha-
amino-3-hydroxy-5-methyl-4-isoxazolepropionate.
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Fig. 2. NF-jB signaling in neuroprotection. Interleukin-1b, S100 cal-
cium-binding protein B (S100B), leptin and glutamate, through the
stimulation of mGlu5 receptors, activate NF-jB c-Rel dimers, but
not the p50 ⁄ p65 complex. These agents also activate the MEK ⁄
PI3K ⁄ PKC signaling pathways that are upstream of c-Rel dimer
translocation to the nucleus. The p50 ⁄ c-Rel and p65 ⁄ c-Rel dimers
mediate neuroprotection by inducing the expression of the anti-
apoptotic genes manganese superoxide dismutase (MnSOD) and
Bcl-X(L). AKT, CHPG.
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inhibition are detrimental [88]. To analyse which sub-
unit of NF-jB is involved in stroke, focal cerebral
ischemia was induced in mice with selective deletion of
p50 [50], p52 or c-Rel, or with conditional deletion of
p65 [54]. These studies show that only mice deﬁcient in
p50 or p65 have a reduced infarct size when exposed
to middle cerebral artery occlusion (MCAO). In order
to examine the speciﬁc assembly of NF-jB subunits
that form active dimers in response to ischemia in neu-
ronal cells, together with their role in cell resistance to
ischemia, primary cortical cells were exposed to oxy-
gen-glucose deprivation (OGD), an established in vitro
model of cerebral ischemia, and mice were subjected to
permanent MCAO. It was found that the p50 ⁄p65
complex is activated in neurons during OGD as well
as in ischemic brain areas of mice exposed to MCAO,
whereas the c-Rel-containing dimers, c-Rel ⁄p50 and
c-Rel ⁄p65, decrease (Fig. 1). Targeting p65 by speciﬁc
small interfering RNA molecules rescues neuronal cells
from the anoxic injury, whereas targeting the c-Rel
factor enhances neuronal susceptibility [89]. Thus, if
the p50 ⁄p65 dimer leads to cell death, the c-Rel-con-
taining complexes drive neuroprotection. The contrast-
ing effects played by p50 ⁄p65 and c-Rel dimers on
neuronal cell survival rely on transcription of the Bcl-2
family genes that act as major regulators of apoptosis
in brain ischemia [54,90,91]. The concentrations of
pro-apoptotic Bcl-2 family members, such as the BH3-
only proteins Bim and Noxa, increase during brain
ischemia and are transcriptionally regulated by the p65
subunit in neuronal cells (Fig. 1) [54]. Conversely, the
anti-apoptotic Bcl-X(L) gene is transcriptionally acti-
vated by c-Rel homodimers and heterodimers, but not
by the p50 ⁄p65 complex (Fig. 2) [89]. As a demonstra-
tion of this, the content of Bcl-X(L) decreases in dying
ischemic neurons and is retained in surviving cells
[92–94].
The adipocyte-derived hormone leptin that strongly
activates c-Rel-containing dimers such as c-Rel ⁄p50
and c-Rel ⁄p65, but not p50 ⁄p65, signiﬁcantly reduces
the infarct volume in mice exposed to permanent
MCAO and rescues neurons from OGD-mediated
apoptosis [24]. Both leptin-induced NF-jB activation
and neuroprotection are dependent on the PI3K,
MEK and PKC activity, the signalling pathways also
involved in c-Rel activation and c-Rel-dependent main-
tenance of hippocampal LTD by agonists of mGlu5
receptors [23]. Leptin-mediated in vitro and in vivo
neuroprotection is associated with expression of the
Bcl-X(L) gene. The beneﬁcial effect of leptin is sup-
pressed in c-Rel) ⁄ ) mice exposed to MCAO as well as
in c-Rel) ⁄ ) neuronal culture deprived of oxygen and
glucose, conﬁrming the pivotal role of c-Rel dimers in
mediating the anti-apoptotic activity of the hormone.
It is worthy of note that while neurons acutely silenced
for c-Rel protein are more vulnerable to the anoxic
injury, mice or cortical neurons carrying a germline
deletion of c-Rel show no enhanced susceptibility to
ischemia [54]; however, they become unresponsive to
c-Rel-mediated neuroprotection by anti-apoptotic
agents [24,71]. This suggests that c-Rel can be replaced
by other NF-jB factors, during development, to guar-
antee the threshold of neuron vulnerability, but that it
exerts a unique role in anti-apoptotic mechanisms
acutely activated by neuroprotective agents to revert
neurodegeneration.
Conclusions
In brain ischemia, NF-jB is involved in excitotoxic,
oxidative and inﬂammatory events associated with neu-
rodegeneration by displaying a dual role in the modula-
tion of neuron survival. It has been proposed that the
contrasting effects of NF-jB may depend on a different
type of stimulus or target cell. According to this
concept, NF-jB is neuroprotective when activated in
neurons and is neurotoxic when induced in glial cells
[60]. Recent progress in understanding the NF-jB
dichotomy shows that within the same neuronal cell,
unbalanced activation of the NF-jB p50 ⁄p65 dimer
over c-Rel-containing complexes contributes to cell
death secondary to the ischemic insult. While p50p ⁄p65
promotes transcription of the pro-apoptotic Bcl-2 fam-
ily members Bim and Noxa, c-Rel dimers speciﬁcally
induce the Bcl-X(L) gene. Modiﬁcation of the nuclear
content of c-Rel dimers strongly affects the threshold
of neuron vulnerability to anoxic injury. Drugs that by
activating c-Rel-dependent transcription prevent neuro-
nal apoptosis, such as leptin display neuroprotective
activity. This latest data, by focusing on the speciﬁc
role of different NF-jB components in neuronal cell
survival, suggest that selective inducers of c-Rel dimers,
as well as speciﬁc inhibitors of aberrantly activated
p50 ⁄p65 complexes, should have much higher beneﬁcial
effects in treating ischemia than the general blockers of
the NF-jB pathway tested to date.
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